低分子肝素辅助治疗AECOPD并肺心病患者的效果及对患者心功能和凝血功能的影响

Effect and Safety of Low Molecular Weight Heparin in Adjuvant Treatment of AECOPD Patients with Pulmonary Heart Disease and Influence on Cardiac Function and Coagulation Function of Patients

目的:探究低分子肝素钙(LMWHC)治疗慢性阻塞性肺疾病急性加重期(AECOPD)并肺心病患者的效果。方法:选取2017年8月-2019年8月于笔者所在医院就诊的AECOPD合并肺心病的患者94例,按照随机数字表法分为对照组和研究组,各47例。对照组予以常规治疗,研究组在对照组的基础上联合LMWHC治疗,观察两组患者临床疗效、心功能及凝血功能。结果:研究组总有效率(95.74%)明显高于对照组(80.85%),差异有统计学意义(P<0.05)。治疗后,研究组EDV、ESV水平和D-D水平明显低于对照组(P<0.05),RVEF水平和PT、APTT水平明显高于对照组(P<0.05)。结论:低分子肝素钙治疗AECOPD并肺心病的临床效果显著,可有效改善患者心功能和凝血功能情况。

Objective:To explore the effect of Low Molecular Weight Heparin Calcium(LMWHC)in the treatment of patients with acute exacerbation chronic obstructive pulmonary disease(AECOPD)and pulmonary heart disease.Method:A total of 94 patients with AECOPD and pulmonary heart disease in our hospital from August 2017 to August 2019 were selected and divided into control group and study group by random table method,47 cases in each group.The control group was given conventional treatment,and the study group was treated with LMWHC on the basis of the control group.The clinical efficacy,cardiac function and coagulation function of the two groups were observed.Result:The total effective rate of the study group(95.74%)was significantly higher than 80.85%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of EDV,ESV and D-D in the study group were significantly lower than those in the control group(P<0.05),and the levels of RVEF,PT and APTT in the study group were significantly higher than those in the control group(P<0.05).Conclusion:The clinical effect of Low Molecular Weight Heparin Calcium in the treatment of AECOPD with pulmonary heart disease is significant,which can effectively improve the cardiac function and coagulation function of patients.